Evaluation of Real-World Vancomycin Dosing and Attainment of Therapeutic Drug Monitoring Targets

Evaluation of Real-World Vancomycin Dosing and Attainment of Therapeutic Drug Monitoring Targets

In 2020, the Infectious Diseases Society of America (IDSA) recommended a change in vancomycin therapeutic drug monitoring from trough-based to AUC/MIC-based to optimize vancomycin’s efficacy and reduce nephrotoxicity. Many hospitals have not implemented this change due to barriers such as the cost o...

Full description

Bibliographic Details
Main Authors:	Nicole Bradley, Kimberly Ng
Format:	Article
Language:	English
Published:	MDPI AG 2023-06-01
Series:	Pharmacy
Subjects:	vancomycin pharmacokinetics therapeutic drug monitoring AUC/MIC ratio
Online Access:	https://www.mdpi.com/2226-4787/11/3/95

Similar Items

Therapeutic drug monitoring of vancomycin by AUCτ-MIC ratio in patients with chronic kidney disease
by: Ahmad Khoei, et al.
Published: (2019-01-01)

A Monocentric Retrospective Study of AUC/MIC Ratio of Vancomycin Associated with Clinical Outcomes and Nephrotoxicity in Patients with Enterococcal Infections
by: Wasan Katip, et al.
Published: (2021-08-01)

Predicting Antibiotic Effect of Vancomycin Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation: Dense Sampling versus Sparse Sampling
by: Yong Kyun Kim, et al.
Published: (2022-05-01)

Association of vancomycin trough concentration on the treatment outcome of patients with bacteremia caused by Enterococcus species
by: Yujin Sohn, et al.
Published: (2021-10-01)

Pharmacokinetic/pharmacodynamic parameters of vancomycin for predicting clinical outcome of enterococcal bacteremia
by: Eliel Nham, et al.
Published: (2022-08-01)

Vancomycin Area under the Concentration-Time Curve Estimation Using Bayesian Modeling versus First-Order Pharmacokinetic Equations: A Quasi-Experimental Study
by: Yazed Saleh Alsowaida, et al.
Published: (2022-09-01)

Treatment of Intracranial Infection Caused by Methicillin-Resistant Staphylococcus epidermidis with Linezolid Following Poor Outcome of Vancomycin Therapy: A Case Report and Literature Review
by: Fu X, et al.
Published: (2021-07-01)

Association between single trough-based area under the curve estimation of vancomycin and treatment outcome among methicillin-resistant Staphylococcus aureus bacteremia patients
by: Mohd Makmor-Bakry, et al.
Published: (2019-08-01)

Bayesian method application: Integrating mathematical modeling into clinical pharmacy through vancomycin therapeutic monitoring
by: Ashley Chen, et al.
Published: (2022-12-01)

Therapeutic drug monitoring of vancomycin in patients with infectious complications in traumatology and orthopedics
by: Borisov A.M., et al.
Published: (2020-03-01)

Characteristics and calculations of paired vancomycin measurements for determination of 24-h area-under-curve (AUC)
by: Yutao Deng, et al.
Published: (2023-03-01)

Critical assessment of the revised guidelines for vancomycin therapeutic drug monitoring
by: Abdullah Aljutayli, et al.
Published: (2022-11-01)

Vancomycin AUC-Based Dosing Practices in a Non-Teaching Community Hospital and Associated Outcomes: A One-Year Survey of Uniform Targets for Infections with or without MRSA
by: Iftekharul Islam
Published: (2024-01-01)

Pharmacokinetics and Pharmacodynamics of Florfenicol in Plasma and Synovial Fluid of Pigs at a Dose of 30 mg/kg<sub>bw</sub> Following Intramuscular Administration
by: Zoltán Somogyi, et al.
Published: (2023-04-01)

What Is the Best Vancomycin Therapeutic Drug Monitoring Parameter to Assess Efficacy? A Critical Review of Experimental Data and Assessment of the Need for Individual Patient Minimum Inhibitory Concentration Value
by: Bruce R. Dalton
Published: (2023-02-01)

The monitoring of vancomycin: a systematic review and meta-analyses of area under the concentration-time curve-guided dosing and trough-guided dosing
by: Moeko Tsutsuura, et al.
Published: (2021-02-01)

Evaluation of the Association between Trough and Area Under the Curve to Minimum Inhibitory Concentration Ratio (AUC24/MIC) of Vancomycin in Infected Patients with Methicillin Resistant Staphylococcus aureus (MRSA)
by: Ayda Esmaeili, et al.
Published: (2021-06-01)

Synovial and Systemic Pharmacokinetics of Florfenicol and PK/PD Integration against <i>Streptococcus suis</i> in Pigs
by: Zoltán Somogyi, et al.
Published: (2022-01-01)

Pharmacokinetics and therapeutic target attainment of vancomycin in pediatric post-liver transplant patients
by: Ronaldo Morales Junior, et al.
Published: (2023-11-01)

Therapeutic Drug Monitoring of Vancomycin Concentrations for the Management of Bone and Joint Infections: An Urgent Need
by: Laura Rio-No, et al.
Published: (2023-02-01)

Model-Informed Precision Dosing of Vancomycin in Hospitalized Children: Implementation and Adoption at an Academic Children’s Hospital
by: Adam Frymoyer, et al.
Published: (2020-04-01)

Practical approaches to improve vancomycin-related patient outcomes in pediatrics- an alternative strategy when AUC/MIC is not feasible
by: Kashif Hussain, et al.
Published: (2022-08-01)

Early Vancomycin Concentrations and the Applications of a Pharmacokinetic Extrapolation Method to Recognize Sub-Therapeutic Outcomes
by: Oscar Santalo, et al.
Published: (2016-11-01)

Discrepancy in Vancomycin AUC/MIC Ratio Targeted Attainment Based upon the Susceptibility Testing in Staphylococcus aureus
by: Seenae Eum, et al.
Published: (2016-09-01)

Evaluation of Therapeutic Vancomycin Monitoring in Taiwan
by: Tzu-Ting Chen, et al.
Published: (2022-04-01)

Systematic Comparison of Hospital-Wide Standard and Model-Based Therapeutic Drug Monitoring of Vancomycin in Adults
by: Heleen Gastmans, et al.
Published: (2022-07-01)

Candidates for area under the concentration–time curve (AUC)-guided dosing and risk reduction based on analyses of risk factors associated with nephrotoxicity in vancomycin-treated patients
by: Naoto Hashimoto, et al.
Published: (2021-12-01)

Therapeutic drug monitoring of vancomycin in an obese patient with renal insufficiency
by: Said Abuhasna, et al.
Published: (2011-01-01)

Clinical Application Value of Pharmacokinetic Parameters of Vancomycin in Children Treated in the Pediatric Intensive Care Unit
by: Bo Zhou, et al.
Published: (2022-06-01)

Population Pharmacokinetics of Vancomycin in Kidney Transplant Recipients: Model Building and Parameter Optimization
by: Kui-fen Ma, et al.
Published: (2020-10-01)

Therapeutic monitoring of vancomycin according to initial dosing regimen in pediatric patients
by: Dae Il Kim, et al.
Published: (2010-12-01)

Comparison of vancomycin serum levels prior to and post therapeutic drug monitoring in patients admitted to hospital
by: Kaveh Eslami, et al.
Published: (2021-09-01)

Vancomycin treatment: analysis of efficacy and safety
by: Brigita Mavsar-Najdenov, et al.
Published: (2007-11-01)

Clinical Response and Hospital Costs of Therapeutic Drug Monitoring for Vancomycin in Elderly Patients
by: Yun Kim, et al.
Published: (2022-01-01)

Sorting Out the Risks and Benefits of the #797 Recommended Intrapartum Vancomycin Dosing Approach
by: Andras Farkas, et al.
Published: (2022-12-01)

Vancomycin Flight Simulator: A Team-Based Learning Exercise
by: Nicholas W. Carris, et al.
Published: (2023-01-01)

Occurrence of vancomycin MIC creep in methicillin resistant isolates in Saudi Arabia
by: Sameerah Aljohani, et al.
Published: (2020-10-01)

Assessment of Initial Vancomycin Dosing in Pediatric Oncology Patients
by: Hillary Orr, et al.
Published: (2017-08-01)

Pharmacokinetics of vancomycin in adults receiving extracorporeal membrane oxygenation
by: Chien-Chih Wu, et al.
Published: (2016-07-01)

Cerebrospinal Fluid Concentrations of Meropenem and Vancomycin in Ventriculitis Patients Obtained by TDM-Guided Continuous Infusion
by: Christoph Tiede, et al.
Published: (2021-11-01)